Document Detail

Formoterol protects against platelet-activating factor-induced effects in asthma.
MedLine Citation:
PMID:  14738234     Owner:  NLM     Status:  MEDLINE    
Platelet-activating factor (PAF) is an inflammatory mediator that provokes neutropaenia, bronchoconstriction and gas exchange defects due to exudation of bulk plasma within the airways. While the inhibitory effects of short-acting beta2-agonists on PAF-induced disturbances have been consistently shown, those of long-acting beta2-agonists are less convincing. To further explore the mechanisms involved in PAF challenge in asthma, 12 patients (forced expiratory volume in one second, 90 +/- 4% predicted) were investigated 2 h after inhaled formoterol (18 microg), in a double-blind, placebo-controlled, crossover design following PAF (18 microg) inhalation. Compared with the placebo, at 5 min, premedication with formoterol reduced PAF-induced cough and dyspnoea, and attenuated increased respiratory system resistance (by 67%) and arterial deoxygenation (by 50%). Likewise, ventilation-perfusion (V'A/Q') inequality improved, as reflected by the dispersion of pulmonary blood flow (by 63%) and an overall index of V'A/Q' heterogeneity (by 71%). In contrast, PAF-induced facial flushing, neutropaenia and subsequent rebound neutrophilia remained unchanged. The improvement in gas exchange abnormalities shown after platelet-activating factor in patients with asthma pretreated with formoterol at the recommended clinical dose may reflect, in addition to its class effects, an anti-exudative effect of formoterol in the airways.
J Gabrijelcic; A Casas; R A Rabinovich; J Roca; J A Barberà; K F Chung; R Rodríguez-Roisin
Related Documents :
2520484 - The role of platelet activating factor in allergic inflammation.
12352314 - Platelet-activating factor enhanced the pressor response of endothelin-1.
2003804 - Synthesis of platelet activating factor by ocular tissue from inflamed eyes.
2629894 - Absence of a lyso-paf relationship with paf (platelet activating factor) in monosodium ...
12925034 - Marked increase in vascular endothelial growth factor concentrations during escherichia...
19300254 - Hemostasis and coagulation monitoring and management during liver transplantation.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The European respiratory journal     Volume:  23     ISSN:  0903-1936     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2004-01-23     Completed Date:  2004-04-27     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  71-5     Citation Subset:  IM    
Servei de Pneumologia i Al.lèrgia Respiratòria (ICPCT), Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Adrenergic beta-Agonists / administration & dosage,  therapeutic use*
Airway Resistance / drug effects
Asthma / drug therapy,  physiopathology*
Cough / prevention & control
Cross-Over Studies
Double-Blind Method
Dyspnea / prevention & control
Ethanolamines / administration & dosage,  therapeutic use*
Flushing / prevention & control
Neutropenia / prevention & control
Platelet Activating Factor / adverse effects*
Pulmonary Circulation / drug effects
Pulmonary Gas Exchange / drug effects
Ventilation-Perfusion Ratio / drug effects
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Ethanolamines; 0/Platelet Activating Factor; 5ZZ84GCW8B/formoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Childhood factors that predict asthma in young adulthood.
Next Document:  Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthm...